Larissa-Nele Schaffert

Ms. Larissa-Nele Schaffert

University of Nottingham

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
LSLarissa-Nele Schaffert
Larissa-Nele Schaffert
Wayne CarterWayne Carter
Wayne Carter
The accumulation of abnormal protein aggregates represents a universal hallmark of neurodegenerative diseases (NDDs). Post-translational modifications (PTMs) regulate protein structure and function. Dysregulated PTMs may influence the propensity for protein aggregation in NDD-proteinopathies. To investigate this, we systematically reviewed the literature to evaluate effects of PTMs on aggregation propensity for major proteins linked to the pathogenesis and/or progression of NDDs. A search of PubMed, MEDLINE, EMBASE, and Web of Science Core Collection was conducted to retrieve studies that investigated an association between PTMs and protein aggregation in seven NDDs: Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxias, transmissible spongiform encephalopathy, and multiple sclerosis. Together, 1222 studies were identified, of which 69 met eligibility criteria. We identified that the following PTMs, in isolation or combination, potentially act as modulators of proteinopathy in NDDs: isoaspartate formation in Aβ, phosphorylation of Aβ or tau in AD; acetylation, 4-hydroxy-2-neonal modification, O-GlcNAcylation or phosphorylation of α-synuclein in PD; acetylation or phosphorylation of TAR DNA-binding protein-43 in ALS, and SUMOylation of superoxide dismutase-1 in ALS; and phosphorylation of huntingtin in HD. The potential pharmacological manipulation of these aggregation-modulating PTMs represents an as-yet untapped source of therapy to treat NDDs.

1 November 2021
Verified
Book Chapter
Closed access
PDF file
LSLarissa-Nele Schaffert
Larissa-Nele Schaffert
Wayne CarterWayne Carter
Wayne Carter
Millions of people worldwide suffer from neurodegenerative diseases (NDDs), with numbers continuing to rise, in part due to increased longevity. This has resulted in an economic and social global burden of epidemic proportions. While most NDDs share a common pathology of neuronal dysfunction and death and proteinopathic changes, the precise mechanisms that trigger protein misfolding and conversion to abnormally toxic oligomeric and aggregated proteins remain poorly understood. Consequently, the critical steps that precede protein aggregation and protein deposition in the brain have only been partly posited.